G
Giuseppe Mancia
Researcher at University of Milano-Bicocca
Publications - 1465
Citations - 152794
Giuseppe Mancia is an academic researcher from University of Milano-Bicocca. The author has contributed to research in topics: Blood pressure & Ambulatory blood pressure. The author has an hindex of 145, co-authored 1369 publications receiving 139692 citations. Previous affiliations of Giuseppe Mancia include University of Milan & Instituto Politécnico Nacional.
Papers
More filters
Journal ArticleDOI
Predictors of Adverse Outcome Among Patients With Hypertension and Coronary Artery Disease
Carl J. Pepine,Peter R. Kowey,Stuart Kupfer,R. Kolloch,Athanase Benetos,Giuseppe Mancia,Antonio Coca,Rhonda M. Cooper-DeHoff,Eileen M. Handberg,Efrain Gaxiola,Peter Sleight,C. Richard Conti,Ann C. Hewkin,Luigi Tavazzi,Invest Investigators +14 more
TL;DR: In hypertensive patients with CAD, increased risk for adverse outcomes was associated with conditions related to the severity of CAD and diminished left ventricular function, and lower follow-up BP and addition of trandolapril to verapamil SR each were associated with reduced risk.
Journal ArticleDOI
An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
TL;DR: Irbesartan was more effective than valsartan in reducing DBP and SBP at trough and in providing greater overall 24-h blood pressure-lowering efficacy.
Journal ArticleDOI
Normal values of left-ventricular mass: echocardiographic findings from the PAMELA study.
Cesare Cuspidi,Rita Facchetti,Carla Sala,Michele Bombelli,Francesca Negri,Stefano Carugo,Roberto Sega,Guido Grassi,Giuseppe Mancia +8 more
TL;DR: The investigation by providing upper reference limits of left-ventricular mass in a southern European population sample, carefully selected after exclusion of a large number of conditions affecting left- ventricular mass, may offer a contribution for revising diagnostic criteria of echocardiographic LVH currently recommended by European hypertension guidelines.
Journal ArticleDOI
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Sripal Bangalore,Franz H. Messerli,Jerome D. Cohen,Peter Bacher,Peter Sleight,Giuseppe Mancia,Peter R. Kowey,Qian Zhou,Annette Champion,Carl J. Pepine +9 more
TL;DR: In hypertensive patients with prior MI, a verapamil-SR- based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verap amil- SR-based group.
Journal ArticleDOI
Sympathetic Mechanisms, Organ Damage, and Antihypertensive Treatment
TL;DR: Evidence collected over the past few years documenting the importance of neurogenic factors in the development and progression of end-organ damage and the therapeutic implications of this evidence are reviewed.